December 31, 2023 · Form 4 insider transaction
Theagene Jean-Manasse bought 15,418 shares of MAIA at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 3 days after the transaction.
The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.